Verovaccines
VEROVACCiNES GmbH is a biotechnology company specializing in the rapid development of animal vaccines using an integrated subunit vaccine platform based on recombinant strains of the yeast Kluyveromyces lactis. Their mission is to bring vaccines to registration quickly and offer advantages along the entire value chain from vaccine design to commercialization, with a focus on innovative solutions for animal health.
Industries
Nr. of Employees
small (1-50)
Verovaccines
Blücherstraße 26, 06120 Halle (Saale), Germany
Patents
Optimized host/vector system for producing protective mono- and multivalent subunit vaccines on the basis of the yeast Kluyveromyces lactis
US-11905517-B2
View DetailsVaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens
US-11065312-B2
View Details
Optimized host/vector system for producing protective mono- and multivalent subunit vaccines on the basis of the yeast Kluyveromyces lactis
US-11905517-B2
View DetailsVaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens
US-11065312-B2
View DetailsProducts
Recombinant subunit vaccine candidate for bluetongue virus serotype 3 (BTV-3)
A recombinant subunit vaccine candidate generated against the BTV-3 outbreak using a yeast-based antigen expression approach; reported as produced within weeks and progressed toward dossier completion within nine months.
Recombinant subunit vaccine candidate for bluetongue virus serotype 3 (BTV-3)
A recombinant subunit vaccine candidate generated against the BTV-3 outbreak using a yeast-based antigen expression approach; reported as produced within weeks and progressed toward dossier completion within nine months.
Services
End-to-end development service for animal vaccines leveraging a recombinant yeast expression platform to generate and optimize antigen constructs, progress validation studies, and support regulatory dossier preparation for registration.
End-to-end development service for animal vaccines leveraging a recombinant yeast expression platform to generate and optimize antigen constructs, progress validation studies, and support regulatory dossier preparation for registration.
Expertise Areas
- Animal vaccine development
- Subunit vaccine design
- Recombinant protein expression in yeast
- Preclinical validation and species-specific testing
Key Technologies
- Recombinant yeast expression (Kluyveromyces lactis)
- Subunit vaccine technology
- Multivalent vaccine design
- Rapid vaccine construct generation
News & Updates
VEROVACCiNES attended the Leipzig Veterinary Congress to update on animal health needs, extend professional networks, and learn about new vaccine applications.
VEROVACCiNES participated in the European animal health innovation summit in London, showcasing their vaccine technology.
VEROVACCiNES presented their multivalent subunit marker vaccine development at the VetHealth Global conference in Canada.
VEROVACCiNES participated in the Animal AgTech Innovation Summit in Amsterdam, gathering leaders from agribusiness, livestock, and technology sectors.
VEROVACCiNES attended the investment forum in London, showcasing investment opportunities in animal health.
VEROVACCiNES presented their vaccine development at the Lisbon congress, discussing innovative vaccine technologies.
VEROVACCiNES attended the Leipzig Veterinary Congress to update on animal health needs, extend professional networks, and learn about new vaccine applications.
VEROVACCiNES participated in the European animal health innovation summit in London, showcasing their vaccine technology.
VEROVACCiNES presented their multivalent subunit marker vaccine development at the VetHealth Global conference in Canada.
VEROVACCiNES participated in the Animal AgTech Innovation Summit in Amsterdam, gathering leaders from agribusiness, livestock, and technology sectors.
VEROVACCiNES attended the investment forum in London, showcasing investment opportunities in animal health.
VEROVACCiNES presented their vaccine development at the Lisbon congress, discussing innovative vaccine technologies.